Non-Insulin Therapies For Diabetes Market Report 2026

Non-Insulin Therapies For Diabetes Market Overview

• Non-Insulin Therapies For Diabetes market size has reached to $21.21 billion in 2025 • Expected to grow to $28.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.9% • Growth Driver: Role of Non-Insulin Therapies in Addressing the Global Diabetes Epidemic • Market Trend: Advancements In Non-Insulin GLP-1 Therapies Enhance Treatment Outcomes In Diabetes And Weight Management • North America was the largest region in 2025.

What Is Covered Under Non-Insulin Therapies For Diabetes Market?

Non-insulin therapies for diabetes refer to medications and treatments used to manage blood sugar levels in diabetic patients without the use of insulin injections. They are essential for regulating blood sugar levels in patients, who either do not need or prefer insulin injections. The main classes of drugs in non-insulin therapies for diabetes market are biguanides, sulfonylureas, thiazolidinedione’s, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. Biguanides are oral hypoglycemic agents that treat type 2 diabetes by reducing liver glucose production and enhancing insulin sensitivity. These medications are available for administration via oral and intramuscular routes and are distributed through various channels, including retail pharmacies, hospital pharmacies, and online pharmacies. They are used for monitoring, diagnosis, treatment, and others.

What Is The Non-Insulin Therapies For Diabetes Market Growth Forecast?

The non-insulin therapies for diabetes market size is expected to see strong growth in the next few years. It will grow to $28.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rise in adoption of non-insulin drug combinations, increasing use of glp-1 and sglt2 inhibitors, expansion of online pharmacy channels, growing personalized and precision medicine approaches, advancing integration of digital health and remote monitoring. Major trends in the forecast period include rising adoption of personalized diabetes management, increasing use of ai-driven glucose monitoring systems, growing integration of telemedicine-linked therapy solutions, expanding implementation of data-driven clinical decision support, advancing deployment of connected devices for remote patient care.

Global Non-Insulin Therapies For Diabetes Market Segmentation

1) By Type: Biguanides, Sulfonylureas, Thiazolidinediones (TZDs), DPP 4 Inhibitors, GLP 1 Analogs Or Agonists, SGLT2 Inhibitors 2) By Route Of Administration: Oral, Injectable 3) By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End User: Hospitals Or Clinics, Homecare Or Patients, Other End-Users Subsegments: 1) By Biguanides: Metformin, Combination Of Metformin With Other Drugs 2) By Sulfonylureas: Glimepiride, Glipizide, Glyburide 3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone 4) By DPP 4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin 5) By GLP 1 Analogs Or Agonists: Exenatide, Liraglutide, Dulaglutide 6) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin

What Is The Driver Of The Non-Insulin Therapies For Diabetes Market?

The increase in the prevalence of diabetes is expected to propel the growth of non-insulin therapies for the diabetes market going forward. Diabetes is a chronic medical condition characterized by high blood glucose (sugar) levels. It occurs when the body cannot produce enough insulin or properly use the insulin it makes. The cases of diabetes is growing due to sedentary lifestyles, unhealthy diets, genetic predisposition, aging populations, obesity, ethnicity, lack of awareness, limited access to healthcare, and environmental factors. Non-insulin therapies for diabetes help treat the condition by improving insulin sensitivity, reducing glucose production in the liver, increasing glucose uptake in muscle cells, and enhancing overall glycemic control. For instance, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government agency, the GP-recorded prevalence of type 2 diabetes among adults aged 17 and over rose to 7.0%, up from 6.8% in March 2023. Therefore, the increase in the prevalence of diabetes is driving the growth of non-insulin therapies for the diabetes market.

Key Players In The Global Non-Insulin Therapies For Diabetes Market

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

Global Non-Insulin Therapies For Diabetes Market Trends and Insights

Major companies operating in the non-insulin therapies for diabetes market are focusing on developing advanced solutions, such as non-insulin GLP-1 receptor agonist, to expand treatment options, improve glycemic control, and strengthen their competitive position in the diabetes and obesity care landscape. Non-insulin GLP-1 receptor agonist launch refers to the introduction of therapies that target GLP-1 receptors to support blood glucose regulation and weight reduction without the use of insulin. For instance, in March 2025, Eli Lilly and Company, a US-based pharmaceutical company specializing in diabetes and metabolic therapies, launched Mounjaro (tirzepatide) in India following approval from the Central Drugs Standard Control Organisation. Designed as a dual GIP and GLP-1 receptor agonist, Mounjaro addresses key challenges in type 2 diabetes and obesity management by offering once-weekly subcutaneous administration, enhancing glycemic control, reducing appetite, slowing gastric emptying, and supporting significant weight reduction, with dosing options starting at 2.5 mg and 5 mg to improve patient adherence and long-term outcomes.

What Are Latest Mergers And Acquisitions In The Non-Insulin Therapies For Diabetes Market?

In August 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired Sigilon Therapeutics Inc. for $309.6 million. This acquisition enables Lilly to advance its research and development of encapsulated cell therapies, such as SIG-002, for treating type 1 diabetes. The aim is to offer improved solutions that relieve individuals with type 1 diabetes from continuous disease management. Sigilon Therapeutics Inc. is a US-based biopharmaceutical company developing encapsulated cell therapies for treating type 1 diabetes.

Regional Outlook

North America was the largest region in the non-insulin therapies for diabetes market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Insulin Therapies For Diabetes Market?

The non-insulin therapies for diabetes market consist of sales of glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, oral medications such as metformin and sulfonylureas, and injectable medications such as glp-1 receptor agonists. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Insulin Therapies For Diabetes Market Report 2026?

The non-insulin therapies for diabetes market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-insulin therapies for diabetes industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.